Moderna Generational Yolo Territory Part 3 and final.

=== SUMMARY === - Author’s thesis: Moderna (MRNA) is a “generational YOLO” and still undervalued despite a big run; price target is $250–$300. - He cites ~$60B market cap, Keytruda’s ~$20B annual revenue benchmark, a Merck profit-sharing agreement, and still-high short interest as setup for another squeeze. - He claims the recent pump was a gamma squeeze, not a short covering event, so a larger move could follow. Quality assessment: Speculative retail DD with some valuation framing, but heavily reliant on squeeze mechanics, vague cancer-market assumptions, and an unclear drug (“intersimeran”) revenue outlook. Not institutional-grade research. === SENTIMENT === BULLISH === TRADE IDEAS === MRNA - LONG | confidence: 0.72 | sentiment: +0.7 Speaker: u/VoidAndOcean Thesis: 1. THE FACT: Author argues MRNA’s market cap is still low relative to existing cancer-therapy revenue benchmarks and future cancer-market opportunity; short interest remains high. 2. THE BRIDGE: High short interest + valuation repricing potential creates a squeeze-friendly setup that could push MRNA toward the author’s $250–$300 target. 3. THE VERDICT: Long MRNA as a momentum/valuation squeeze play, but the higher-conviction part of the thesis depends on speculative long-term drug revenue. 4. RISKS: Short squeezes can reverse sharply; clinical/regulatory setbacks; Merck profit-sharing limits per-drug economics; “intersimeran” revenue is speculative; author already banked $2.4M in profits. Timeframe: medium-term Key Points: - Author targets $250–$300 per share - High short interest may fuel another squeeze - Valuation based on Keytruda revenue comparison - Profit-sharing with Merck reduces upside - Long-term cancer market claim is speculative === COMMENTS SUMMARY === Community sentiment is overwhelmingly congratulatory, with users crediting the DD for 200% and 10x gains. One commenter asks how the author was so confident without insider information and whether LEAPs are still worth buying at this sta